Last reviewed · How we verify
LivaloV
LivaloV is a statin that inhibits HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels.
LivaloV is a statin that inhibits HMG-CoA reductase to reduce cholesterol synthesis and lower LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction.
At a glance
| Generic name | LivaloV |
|---|---|
| Also known as | JW0101+C2102, Period I |
| Sponsor | JW Pharmaceutical |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
LivaloV (pitavastatin) is a selective and potent inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. By blocking this enzyme, it reduces hepatic cholesterol production, leading to decreased serum LDL cholesterol and triglycerides while modestly increasing HDL cholesterol. This mechanism helps reduce cardiovascular risk in patients with dyslipidemia.
Approved indications
- Hypercholesterolemia and dyslipidemia for cardiovascular risk reduction
Common side effects
- Myalgia (muscle pain)
- Elevated liver enzymes
- Headache
- Rhabdomyolysis (rare)
Key clinical trials
- To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension (PHASE3)
- To Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers (PHASE1)
- The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LivaloV CI brief — competitive landscape report
- LivaloV updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI